Olanzapine 7.5 MG Oral Tablet — RxCUI 312079
RxNorm drug concept · Semantic clinical drug
RxCUI 312079
Semantic clinical drug · SCD
● Current RxNorm concept 93 FDA products
274 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI312079
Official nameOlanzapine 7.5 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped93
Package NDCs mapped274
Reported Medicaid activity (SDUD)1,892,382 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Olanzapine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Olanzapine helps bring certain brain chemicals — mainly dopamine and serotonin — back into balance. Depending on what it's prescribed for, it can reduce symptoms of psychosis like...
- What exactly is olanzapine supposed to do for me?
- Honestly, yes — weight gain and changes in blood sugar and cholesterol are real and well-documented with olanzapine. Some people gain a significant amount of weight. Blood sugar ca...
- Will olanzapine make me gain weight or affect my blood sugar?
🕸️ Concept Web — How Olanzapine 7.5 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Olanzapine 7.5 MG Oral Tablet
RxCUI 312079 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Olanzapine
61381IN
-
Olanzapine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Zyprexa
135423BN
-
Zyprexa
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Olanzapine Oral Tablet
373142SCDF -
Olanzapine Oral Product
1159557SCDG -
Olanzapine Pill
1159558SCDG -
Olanzapine Oral Tablet [Zyprexa]
367736SBDF -
Zyprexa Oral Product
1186672SBDG -
Zyprexa Pill
1186673SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Olanzapine Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Olanzapine 7.5 MG
316406SCDC -
Olanzapine 7.5 MG Oral Tablet [Zyprexa]
153047SBD -
Olanzapine 7.5 MG [Zyprexa]
565154SBDC
-
Olanzapine 7.5 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Olanzapine 7.5 MG
SCDC · 316406 -
Olanzapine Oral Tablet
SCDF · 373142 -
Olanzapine Oral Product
SCDG · 1159557 -
Olanzapine Pill
SCDG · 1159558
Brand-Name Concepts
-
Olanzapine 7.5 MG Oral Tablet [Zyprexa]
SBD · 153047 -
Olanzapine 7.5 MG [Zyprexa]
SBDC · 565154 -
Olanzapine Oral Tablet [Zyprexa]
SBDF · 367736 -
Zyprexa Oral Product
SBDG · 1186672 -
Zyprexa Pill
SBDG · 1186673 -
Zyprexa
BN · 135423
📦 FDA Products & Package NDCs
93 products · 274 package NDCs
274 package NDCs map to RxCUI 312079 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 72241-0056-10 | 500 TABLET in 1 BOTTLE (72241-056-10) | Olanzapine | Modavar Pharmaceuticals LLC | 2024-01-17 |
| 72241-0056-11 | 1000 TABLET in 1 BOTTLE (72241-056-11) | Olanzapine | Modavar Pharmaceuticals LLC | 2024-01-17 |
| 72241-0056-22 | 30 TABLET in 1 BOTTLE (72241-056-22) | Olanzapine | Modavar Pharmaceuticals LLC | 2024-01-17 |
| 72303-0835-01 | 30 TABLET in 1 BOTTLE, PLASTIC (72303-0835-1) | OLANZAPINE | HEC Pharm USA Inc. | 2018-11-30 |
| 72303-0836-01 | 30 TABLET in 1 BOTTLE, PLASTIC (72303-0836-1) | OLANZAPINE | HEC Pharm USA Inc. | 2018-11-30 |
| 72303-0837-01 | 30 TABLET in 1 BOTTLE, PLASTIC (72303-0837-1) | OLANZAPINE | HEC Pharm USA Inc. | 2018-11-30 |
| 72303-0838-01 | 30 TABLET in 1 BOTTLE, PLASTIC (72303-0838-1) | OLANZAPINE | HEC Pharm USA Inc. | 2018-11-30 |
| 72303-0839-01 | 30 TABLET in 1 BOTTLE, PLASTIC (72303-0839-1) | OLANZAPINE | HEC Pharm USA Inc. | 2018-11-30 |
| 72303-0840-01 | 30 TABLET in 1 BOTTLE, PLASTIC (72303-0840-1) | OLANZAPINE | HEC Pharm USA Inc. | 2018-11-30 |
| 72603-0154-01 | 30 TABLET, FILM COATED in 1 BOTTLE (72603-154-01) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0154-02 | 90 TABLET, FILM COATED in 1 BOTTLE (72603-154-02) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0154-03 | 1000 TABLET, FILM COATED in 1 BOTTLE (72603-154-03) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0155-01 | 30 TABLET, FILM COATED in 1 BOTTLE (72603-155-01) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0155-02 | 90 TABLET, FILM COATED in 1 BOTTLE (72603-155-02) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0155-03 | 1000 TABLET, FILM COATED in 1 BOTTLE (72603-155-03) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0156-01 | 30 TABLET, FILM COATED in 1 BOTTLE (72603-156-01) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0157-01 | 30 TABLET, FILM COATED in 1 BOTTLE (72603-157-01) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0157-02 | 90 TABLET, FILM COATED in 1 BOTTLE (72603-157-02) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0157-03 | 500 TABLET, FILM COATED in 1 BOTTLE (72603-157-03) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0158-01 | 30 TABLET, FILM COATED in 1 BOTTLE (72603-158-01) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0158-02 | 1000 TABLET, FILM COATED in 1 BOTTLE (72603-158-02) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0159-01 | 30 TABLET, FILM COATED in 1 BOTTLE (72603-159-01) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0159-02 | 500 TABLET, FILM COATED in 1 BOTTLE (72603-159-02) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
| 72603-0159-03 | 1000 TABLET, FILM COATED in 1 BOTTLE (72603-159-03) | Olanzapine | NorthStar RxLLC | 2023-07-05 |
Observed labelers:
Torrent Pharmaceuticals Limited (46) ·
Ascend Laboratories, LLC (36) ·
Macleods Pharmaceuticals Limited (27) ·
Aurobindo Pharma Limited (26) ·
Cadila Pharmaceuticals Limited (24) ·
Modavar Pharmaceuticals LLC (24)
· +10 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.